​

Kezar Life Sciences Stock (NASDAQ:KZR)

ForecastOwnershipFinancialsChart
Kezar Life Sciences by TradingView

Previous Close

$7.27

52W Range

$3.53 - $7.55

50D Avg

$6.97

200D Avg

$5.65

Market Cap

$54.03M

Avg Vol (3M)

$74.01K

Beta

0.43

Div Yield

-

KZR Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Jun 21, 2018

Website

KZR Performance

KZR Financial Summary

Dec 25Dec 24Dec 23
Revenue--$7.00M
Operating Income$-59.11M$-90.61M$-111.42M
Net Income$-56.03M$-83.74M$-101.87M
EBITDA$-59.11M$-81.10M$-99.25M
Basic EPS$-7.66$-1.15$-1.40
Diluted EPS$-7.66$-1.15$-1.40

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 20Aug 09, 20 | 4:30 PM

Peer Comparison

TickerCompany
MRSNMersana Therapeutics, Inc.
OKUROnKure Therapeutics, Inc.
FGENFibroGen, Inc.
TPSTTempest Therapeutics, Inc.
BRNSBarinthus Biotherapeutics plc
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
XFORX4 Pharmaceuticals, Inc.
ALGSAligos Therapeutics, Inc.